本帖最后由 老马 于 2013-3-13 13:43 编辑
, ^% A# H6 I) S$ n, k% q" K& |3 B7 a
健择（吉西他滨）+顺铂+阿瓦斯汀
" X) o* X2 }' v; ]: D# E7 O0 I Gemzar +Cisplatin + Avastin! O& ? B3 K q+ X& b
http://annonc.oxfordjournals.org/content/21/9/1804.full" u% @) B b1 G' q0 u
Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL) 0 I# W$ A9 v H) r
Patients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.
: z! S# R7 Z' z7 pResults: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported. : s( H6 D1 p" J
Cisplatin Gemzar Avastin.PDF
(329.84 KB, 下载次数: 851)
. t3 R! ~' b7 A% w. b/ t! c
华为网盘附件：: V8 U6 K9 f0 {/ t
【华为网盘】ava.JPG
4 ` _1 y l" | |
显身卡
